<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03512119</url>
  </required_header>
  <id_info>
    <org_study_id>6403</org_study_id>
    <nct_id>NCT03512119</nct_id>
  </id_info>
  <brief_title>Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor</brief_title>
  <acronym>GLUCORRECTOR</acronym>
  <official_title>Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cystic Fibrosis related diabetes (CFRD), a major factor of morbid-mortality in CF, is
      characterized by a preclinical phase of glucose intolerance particularly long reaching up to
      10 years.

      At the physiopathology level, insulin secretion is determinant in the glucose tolerance
      abnormalities in CF. Indeed insulin secretion is dependent of the CFTR activity at the beta
      cell surface and inhibition of CFTR leads to a decrease in insulin secretion.

      Recently, the combination of the lumacaftor, a CFTR corrector, with Ivacaftor, a CFTR
      potentiator, was studied in patient with CF homozygous for the Phe508 del CFTR mutation
      patients and showed an improvement of the respiratory state in comparison with the placebo
      group.

      These data suggests that lumacaftor in combination with ivacaftor in targeting CFTR action
      may have an early impact on the insulin-secretion and consequently on the glucose tolerance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2016</start_date>
  <completion_date type="Anticipated">October 10, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of 2 hours plasma glucose value (mmol/l) of OGTT, change from baseline at one year of Lumacaftor-Ivacaftor treatment</measure>
    <time_frame>Day 0 (traitement beginning) and year 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting and one hour glucose value of OGTT (mmol/l)</measure>
    <time_frame>Day 0 (traitement beginning) and year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C peptide and insulin values at T0, 1 , 2 hours of OGTT (µg/l)</measure>
    <time_frame>Day 0 (traitement beginning) and year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose, insulin and C peptide AUC of OGTT (µU/L)</measure>
    <time_frame>Day 0 (traitement beginning) and year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA -R , HOMA-S</measure>
    <time_frame>Day 0 (traitement beginning) and year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean glucose value per day and 2 h after meal (mg/dl)</measure>
    <time_frame>Day 0 (traitement beginning) and year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration in hypoglycemic area [hypo CGM = 2 consecutive values below 3.3 mmol/l - % of time spent]</measure>
    <time_frame>Day 0 (traitement beginning) and year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration in hyperglycemic area [for glucose value higher than 7.7 mmol/l, % time /24h]</measure>
    <time_frame>Day 0 (traitement beginning) and year 1</time_frame>
    <description>Number hypoglycaemic events (below 3.3mmol/L, from midnight to 6 am) Variability glycemic indexes: MAGE (mg/dl), SD (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number hypoglycaemic events (below 3.3mmol/L, from midnight to 6 am)</measure>
    <time_frame>Day 0 (traitement beginning) and year 1</time_frame>
    <description>Variability glycemic indexes: MAGE (mg/dl), SD (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability glycemic indexes: MAGE (mg/dl), SD (mg/dl)</measure>
    <time_frame>Day 0 (traitement beginning) and year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c (mmol/l and %)</measure>
    <time_frame>Day 0 (traitement beginning) and year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily insulin doses (UI/day)</measure>
    <time_frame>Day 0 (traitement beginning) and year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(BMI) body mass index</measure>
    <time_frame>Day 0 (traitement beginning) and year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (Kg) maximum weight never reached</measure>
    <time_frame>Day 0 (traitement beginning) and year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin and Pre albumin (g/l)</measure>
    <time_frame>Day 0 (traitement beginning) and year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1, Vital Capacity (VC) (L and %)</measure>
    <time_frame>Day 0 (traitement beginning) and year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>O2 saturation (%)</measure>
    <time_frame>Day 0 (traitement beginning) and year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cures of antibiotics IV and per os /year and interval between 2 cures (week)</measure>
    <time_frame>Day 0 (traitement beginning) and year 1</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cystic Fibrosis Homozygous for Phe 508 Del CFTR</condition>
  <condition>Glucose Intolerance or Newly Diagnosis Diabetes</condition>
  <arm_group>
    <arm_group_label>Patient</arm_group_label>
    <description>Patient with cystic fibrosis homozygous for Phe 508 del CFTR having a glucose intolerance or newly diagnosis diabetes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumacaftor-Ivacaftor treatment</intervention_name>
    <description>Lumacaftor-Ivacaftor treatment during one year</description>
    <arm_group_label>Patient</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patient with cystic fibrosis homozygous for Phe 508 del CFTR having a glucose intolerance
        or newly diagnosis diabetes
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with CF homozygous for the Phe508del CFTR mutation aged 12 years and over

          -  Combined Lumacaftor-Ivacaftor treatment scheduled or already started

          -  glucose intolerance in OGTT (ADA criteria) or newly diabetes diagnosed at the OGTT
             (ADA criteria) or diabetic patients with insulin requirement ≤ 0.3 unit / kg / day or
             without insulin treatment

          -  signed informed consent of patient and of one parent OR legal representative for minor
             subject

        Exclusion Criteria:

          -  hypersensitivity to the active substances or to any of the excipients of Lumactfor
             -Ivacaftor

          -  lung and/or liver transplant patient

          -  Known diabetes with insulin treatment &gt; 0.3 unit / kg / day

          -  patient pregnant or wishing to pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurence KESSLER, MD</last_name>
    <phone>33388116598</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence KESSLER</last_name>
    </contact>
    <investigator>
      <last_name>Laurence KESSLER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Françoise TROUSSIER</last_name>
    </contact>
    <investigator>
      <last_name>Françoise TROUSSIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Renée Sabran</name>
      <address>
        <city>Giens</city>
        <zip>83406</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent MELY</last_name>
    </contact>
    <investigator>
      <last_name>Laurent MELY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle DURIEU</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle DURIEU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital NORD - Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bérengère COLTEY</last_name>
    </contact>
    <investigator>
      <last_name>Bérengère COLTEY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphael CHIRON</last_name>
    </contact>
    <investigator>
      <last_name>Raphael CHIRON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michèle GERARDIN</last_name>
    </contact>
    <investigator>
      <last_name>Michèle GERARDIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Memorial Hospital</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel ABLEY</last_name>
    </contact>
    <investigator>
      <last_name>Michel ABELY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique &quot;Mucoviscidose&quot; Presqu'île de Perharidy</name>
      <address>
        <city>Roscoff</city>
        <zip>29684</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles RAULT</last_name>
    </contact>
    <investigator>
      <last_name>Gilles RAULT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane DOMINIQUE</last_name>
    </contact>
    <investigator>
      <last_name>Stéphane DOMINIQUE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital FOCH</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence BOUILLOUD</last_name>
    </contact>
    <investigator>
      <last_name>Florence BOUILLOUD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau - CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie MANKIKIAN</last_name>
    </contact>
    <investigator>
      <last_name>Julie MANKIKIAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Clocheville - CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure COSSON</last_name>
    </contact>
    <investigator>
      <last_name>Laure COSSON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>April 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic fibrosis</keyword>
  <keyword>Glucose tolerance abnormalities</keyword>
  <keyword>CFTR corrector and potentiator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

